
IMPACT BIOMEDICAL INC.
71
Recent developments for Impact Biomedical focus on merger activities, reverse stock splits, and share exchange agreements that have significantly impacted the company's share price and corporate structure.
- Impact Biomedical filed Form F-4 with the SEC for a proposed business combination with Zoar Ltd. [N1].
- The company issued a correction on the merger exchange ratio following a reverse stock split that took effect [N2].
- Impact Biomedical announced a reverse stock split to advance its merger with Zoar Ltd. [N3].
- Shares surged over 115% following an amended merger and share exchange agreement [N4].
- Dr Ashleys acquired Impact Biomedical in a reverse merger, leading to a surge in IBO shares [N5].
- Dr Ashleys Limited and Impact Biomedical announced a strategic merger to enhance pharmaceutical innovations [N6].
- An insider owning 10% of IBO sold 53,280 shares in March 2025 [N7].
Impact Biomedical Inc. has been actively involved in strategic mergers and corporate restructuring over recent years. The company merged with Dr Ashleys Limited in 2025 through a reverse merger and is currently advancing a business combination with Zoar Ltd., supported by a reverse stock split and amended merger agreements. The company operates in the pharmaceutical or biomedical sector, focusing on enhancing pharmaceutical innovations through these mergers. Financially, the company reported a net loss and low liquidity ratios as of the third quarter of 2026, indicating ongoing operational and financial challenges.
Impact Biomedical Inc. is a company engaged in merger activities, notably with Zoar Ltd. and Dr Ashleys Limited, as documented in multiple recent news articles and SEC filings. The company has undertaken a reverse stock split to facilitate these mergers. Financial disclosures from the latest SEC 10-Q filing as of September 30, 2026, show limited liquidity with a current ratio of 0.04 and a net loss of $645,000 for the quarter. Financial figures are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice.
The company's strategic mergers with Dr Ashleys Limited and Zoar Ltd. represent significant corporate actions that could enhance its pharmaceutical innovation capabilities. The successful execution of these mergers, including reverse stock splits and amended share exchange agreements, demonstrates management's ability to navigate complex transactions. These developments have been associated with notable share price movements, indicating market interest and potential for increased operational scale.
Impact Biomedical faces financial challenges as indicated by its low liquidity ratios and net losses reported in recent SEC filings. The company's current ratio of 0.04 and cash ratio of 0.01 as of September 30, 2026, suggest limited short-term financial flexibility. The reliance on mergers and reverse stock splits to advance corporate strategy may also introduce execution risks and integration challenges. Insider sales and corrections to merger terms highlight potential governance and transactional risks.
Impact Biomedical's moat appears to be linked to its strategic mergers and business combinations aimed at enhancing pharmaceutical innovations. The company's ability to engage in reverse mergers and complex share exchange agreements suggests a focus on corporate restructuring to build value. However, there is limited disclosed information on proprietary technology, patents, or competitive advantages beyond these merger activities.
• Liquidity Risk: The company has a very low current ratio of 0.04 and cash ratio of 0.01 as of September 30, 2026, indicating limited ability to cover short-term liabilities with current assets.
• Net Losses: Impact Biomedical reported a net loss of $645,000 for the quarter ending September 30, 2026, reflecting ongoing operational challenges.
• Merger Execution Risk: The company is engaged in complex merger transactions involving reverse stock splits and amended exchange ratios, which carry risks related to successful completion and integration.
• Governance and Insider Activity: Insider sales and corrections to merger terms may indicate potential governance issues or uncertainties in corporate transactions.
Business trends: The company is actively pursuing strategic mergers and corporate restructuring to enhance pharmaceutical innovation capabilities.
Execution milestones: Key milestones include completing the reverse merger with Dr Ashleys Limited and advancing the proposed business combination with Zoar Ltd., including reverse stock splits and amended share exchange agreements.
Key risks: Significant risks involve limited liquidity, ongoing net losses, and execution risks related to complex merger transactions and corporate governance uncertainties.
High visibility
Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).
- Impact Biomedical Inc. is involved in merger activities, including a proposed business combination with Zoar Ltd., as evidenced by filing a Form F-4 with the SEC [N1].
- The company announced a reverse stock split to advance the merger with Zoar Ltd. [N3].
- There was a correction issued on the merger exchange ratio following the reverse stock split [N2].
- Impact Biomedical shares surged over 115% following an amended merger and share exchange agreement [N4].
- In 2025, Dr Ashleys Limited announced a strategic merger with Impact Biomedical to enhance pharmaceutical innovations [N6].
- Dr Ashleys acquired Impact Biomedical in a reverse merger, causing a surge in IBO shares [N5].
- An insider owning 10% of IBO sold 53,280 shares in March 2025 [N7].
- As of the quarter ending September 30, 2026, Impact Biomedical reported cash and equivalents of $20,000 and current assets of $102,000, with current liabilities of $2,373,000, resulting in a current ratio of 0.04 and a cash ratio of 0.01 [S2].
- The company reported a net loss of $645,000 and basic and diluted EPS of -$0.08 for the quarter ending September 30, 2026 [S2].
- Financial figures are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice [S2].
Generated 2026-11-10
- S1 | 2026-03-11 | 10-K
- S2 | 2026-11-09 | 10-Q
- N1 | 2026-09-16 | www.nasdaq.com | Impact Biomedical Files Form F-4 For Proposed Zoar Business Combination | https://www.nasdaq.com/articles/impact-biomedical-files-form-f-4-proposed-zoar-business-combination
- N2 | 2026-09-15 | www.nasdaq.com | Impact Biomedical Issues Correction On Merger Exchange Ratio As Reverse Stock Split Takes Effect | https://www.nasdaq.com/articles/impact-biomedical-issues-correction-merger-exchange-ratio-reverse-stock-split-takes-effect
- N3 | 2026-09-14 | www.nasdaq.com | Impact BioMedical Announces Reverse Stock Split To Advance Merger With Zoar Ltd. | https://www.nasdaq.com/articles/impact-biomedical-announces-reverse-stock-split-advance-merger-zoar-ltd
- N4 | 2026-03-05 | www.nasdaq.com | Impact BioMedical Shares Surge Over 115% On Amended Merger And Share Exchange Agreement | https://www.nasdaq.com/articles/impact-biomedical-shares-surge-over-115-amended-merger-and-share-exchange-agreement
- N5 | 2025-06-23 | www.nasdaq.com | Dr Ashleys To Acquire Impact BioMedical In Reverse Merger, IBO Shares Surge | https://www.nasdaq.com/articles/dr-ashleys-acquire-impact-biomedical-reverse-merger-ibo-shares-surge
- N6 | 2025-06-23 | www.nasdaq.com | Dr Ashleys Limited and Impact BioMedical Announce Strategic Merger to Enhance Pharmaceutical Innovations | https://www.nasdaq.com/articles/dr-ashleys-limited-and-impact-biomedical-announce-strategic-merger-enhance-pharmaceutical
- N7 | 2025-03-25 | www.nasdaq.com | Insider Sale: 10% owner at $IBO Sells 53,280 Shares | https://www.nasdaq.com/articles/insider-sale-10-owner-ibo-sells-53280-shares
This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Generated by Valye SEC Pipeline Engine
.gif)


